Theophylline pharmacokinetics was investigated upon introduction of euphylline (0.15 g) at four levels of gastrointestinal tract: orally (20 patients), into the jejunum (15 patients) at enterogastroduodenoscopy, in the ileocecal area (8 patients) at colonoscopy and rectally (9 patients). Absorption speed depended on the variant of the gastrointestinal introduction rather than on the variant of chronic nonspecific intestinal disease, and appeared maximal in the drug introduction into the jejunum. Concentration and area under curve became maximal in minor participation of the liver in primary capture and biotransformation of theophylline. Reduced theophylline doses are recommended in lower hepatic metabolism of the drug, in hepatic hypofunction, in rectal route of administration.
Download full-text PDF |
Source |
---|
Ann Emerg Med
January 2025
Departments of Emergency Medicine & Population Health, New York University Grossman School of Medicine, New York, NY; Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, NY.
Alzheimer's disease is the neurodegenerative disorder responsible for approximately 60% to 70% of all cases of dementia and is expected to affect 152 million by 2050. Recently, anti-amyloid therapies have been developed and approved by the Food and Drug Administration as disease-modifying treatments given as infusions every 2 to 5 weeks for Alzheimer's disease. Although this is an important milestone in mitigating Alzheimer's disease progression, it is critical for emergency medicine clinicians to understand what anti-amyloid therapies are and how they work to recognize, treat, and mitigate their adverse effects.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
December 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Hematology Center, Peking University People's Hospital, Qingdao, China. Electronic address:
Aim: To describe tyrosine kinase inhibitor (TKI) treatment patterns and analyze co-variates of TKI switch for chronic myeloid leukemia (CML) patients in a center from China.
Methods: A retrospectively study was designed to analyze TKI switching patterns, reasons and associated covariates in patients with CP-CML.
Results: 1766 patients receiving initial imatinib (n = 1374), nilotinib (n = 254), dasatinib (n = 63) and flumatinib (n = 75) therapy were retrospectively interrogated.
Spine J
January 2025
Department of Orthopaedic Surgery, University of California, San Francisco.
Background Context: There are a number of risk factors- from biological, psychological, and social domains- for non-specific chronic low back pain (cLBP). Many cLBP treatments target risk factors on the assumption that the targeted factor is not just associated with cLBP but is also a cause (i.e, a causal risk factor).
View Article and Find Full Text PDFPain Rep
February 2025
Department of Occupational Therapy, Graduate School of Rehabilitation Science, Osaka Metropolitan University, Osaka, Japan.
Introduction: Chronic low back pain (CLBP) is a global health issue, and its nonspecific causes make treatment challenging. Understanding the neural mechanisms of CLBP should contribute to developing effective therapies.
Objectives: To compare current source density (CSD) and functional connectivity (FC) extracted from resting electroencephalography (EEG) between patients with CLBP and healthy controls and to examine the correlations between EEG indices and symptoms.
Rev Med Liege
January 2025
Service de Médecine Physique et Traumatologie du Sport, CHU Liège, Belgique.
The prevalence of chronic low back pain is high and rising. Chronic low back pain is «non-specific» in approximately 90 % of cases. In addition to age, risk factors include smoking, obesity, physical and psychological stress, as well as demographic factors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!